• T. Rowe Price Group recently launched three fully transparent, actively managed equity ETFs on NASDAQ, targeting biotech (TDNA), U.S. small caps (TSEE), and U.S. mid caps (TMID), with expense ratios between 0.47% and 0.59%.
• The new ETFs bring the lineup to 38 funds this year and reflect T. Rowe Price Group’s efforts to broaden its products while addressing fee pressure and client demand for tax-efficient, flexible vehicles.
• We will now look at how T. Rowe Price Group’s expanded active ETF lineup could influence its investment narrative and future asset mix.

Spot 16 high quality undiscovered gems that, like T. Rowe Price Group’s new ETFs, aim to combine focused themes with fundamental research and tax-efficient, flexible…